ELOX Eloxx Pharmaceuticals, Inc.
Executive Summary
Eloxx Pharmaceuticals filed an amended S-1 registration statement to offer 1.5 million shares of common stock and pre-funded warrants to purchase up to 4 million shares of common stock at an assumed price of $10.00-$12.00 per share. The company plans to use the net proceeds of approximately $54.2 million to fund Phase 2b and Phase 2 trials of exaluren for Alport syndrome and ADPKD, respectively. The company currently trades on the OTC Pink Limited Market after Nasdaq delisting, has a going concern qualification, and the offering is contingent upon Nasdaq uplisting approval.
Key Financial Metrics
Actionable Insight
The success of this offering is critical for the company to fund its planned Phase 2b and Phase 2 trials and to uplist to Nasdaq. Monitor for pricing details and Nasdaq approval; if the offering closes as planned, it removes near-term going concern risk but significant dilution is expected.
Key Facts
- Offering 1,500,000 shares of common stock and pre-funded warrants for up to 4,000,000 shares at an assumed price of $10.00-$12.00 per share
- Estimated net proceeds of approximately $54.2 million, based on the midpoint of the price range
- Proceeds allocated: $13.2M for exaluren Phase 2b Alport syndrome trial, $19.2M for exaluren Phase 2 ADPKD trial, remainder for working capital
- Company has a going concern qualification with $6.4 million cash as of March 31, 2026 and an accumulated deficit of $304.3 million
- Common stock quoted on OTC Pink; offering contingent on Nasdaq Capital Market listing approval
- Exaluren has received Orphan Drug Designation for Alport syndrome from the FDA
- Net losses of $5.995 million (2025), $3.143 million (2024), and $17.054 million (2023)
Financial Impact
Offering of up to $54.2 million in net proceeds; cash position of $6.4 million as of March 31, 2026; accumulated deficit of $304.3 million; net loss of $3.754 million in Q1 2026
Risk Factors
- Going concern risk if the offering does not close or is delayed
- Nasdaq uplisting approval is a condition of closing — no assurance of approval
- Significant shareholder dilution: pro forma shares outstanding increase from ~461k to ~1.96M (excluding pre-funded warrant exercise)
- Exaluren is the sole pipeline candidate; clinical trial failure would be catastrophic
- Material weakness in internal controls remains unremediated
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-251655 |
| Document: d35071dex11.htm | 0001193125-26-251655 |
| Document: d35071dex1058.htm | 0001193125-26-251655 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
4d ago
|
EFFECT
| $6.20 awaiting T+1 | awaiting T+1 | — | $13.52 (+118.06%) |
|
Jun 4, 2026
8d ago
|
S-1/A
| $6.20 awaiting T+1 | awaiting T+1 | — | $13.52 (+118.06%) |
|
Jun 1, 2026
11d ago
|
S-1/A
| $1.51 $10.00 | ▲ +562.25% | ▲ +562.97% | $13.52 (+795.36%) |
|
Jun 1, 2026
11d ago
|
8-K
| $4.07 $1.51 | ▼ −62.90% | ▼ −63.04% | $13.52 (+232.19%) |
|
May 7, 2026
5w ago
|
S-1
| $1.43 $1.43 | ▼ −0.08% | ▼ −0.30% | $13.52 (+844.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access